A

Allergy Associates of Utah | Murray, UT

Research site
(Unclaimed)
Location
6095 Fashion Boulevard, Suite 100, Murray, Utah, United States of America
Site insights

Top conditions

Urticaria (8 trials)

Chronic Urticaria (6 trials)

Asthma (5 trials)

Angioedema (2 trials)

Hereditary Angioedemas (2 trials)

Top treatments

Remibrutinib
DX-2930
Omalizumab
CDX-0159
LOU064
Briquilimab
LTRA
Lebrikizumab
MSTT1041A
DUPIXENT®

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

6 of 16
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

The purpose of this trial is:to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to < 18 years of...

Enrolling
Chronic Spontaneous Urticaria
Drug: placebo
Drug: LOU064 (blinded)

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in...

Active, not recruiting
Chronic Inducible Urticaria
Biological: barzolvolimab
Drug: Matching Placebo
Locations recently updated

This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension...

Enrolling
Chronic Inducible Urticaria
Other: Placebo
Drug: Remibrutinib
Locations recently updated

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participant...

Enrolling
Chronic Spontaneous Urticaria
Drug: LOU064 (blinded)
Drug: LOU064 (open label)

This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blin...

Enrolling
Chronic Spontaneous Urticaria
Drug: Briquilimab
Other: Placebo

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urtica...

Enrolling
Chronic Spontaneous Urticaria
Drug: Oral EP262
Drug: Placebo

Trial sponsors

Novartis logo

Novartis (4 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems